Development of Methotrexate (MTX) Detection Kit (Fluorescence Immunoassay)

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081977

Enrollment

Unknown

Registered

2024-03-18

Start date

2024-03-23

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, lymphoma, osteosarcoma

Interventions

1:Users of methotrexate drugs with a dose greater than 500mg/?

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Users of methotrexate drugs with a dose greater than 500mg/?

Exclusion criteria

Exclusion criteria: 1) If the sample is stored for more than the expiration date (2-8 ?, stored in dark for more than 4 days); 2) Those who cannot take care of themselves in life; 3) Individuals with no autonomous consciousness or extremely unstable emotions; 4) Other unable to cooperate with sampling and information collectors;

Design outcomes

Primary

Measure	Time frame
Blood concentration of Methotrexate by fluorescence immunochromatography;	—

Secondary

Measure	Time frame
Blood concentration of Methotrexate by mass spectrometry;	—

Countries

China

Contacts

Public ContactMinmin Shen

Huzhou Central Hospital

15715896580@126.com+86 157 1589 6580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026